Interdisciplinary Medication Review Interventions in an Integrated

Status Completed

Clinical Trial Summary

Inappropriate medication prescribing is highly prevalent among comorbid medical patients and leading to adverse drug events (ADE), re-admissions, quality of life and mortality. Thus, the aim of this study is primary to investigate the feasibility of a interdisciplinary intervention focused on deprescribing and medication optimization in the Integrated Outpatient Department at Copenhagen University Hospital, Amager, Denmark. Participants in the intervention group receives a medication review by a clinical pharmacist and physician with a follow up after 7 and 30 days. The control group receives standard care.

Clinical Trial Description

The FMA-CPH trial is designed as a single-blinded randomized controlled pilot trial starting at the first consultation and end 30 days after. Patients that meet all inclusion criteria and none of the exclusion criteria are invited to participate. After signing a written informed consent, the participants are block randomized to either the intervention or control group. Medication prescription for comorbid patients is challenging and may be attributed to marked inter-individual variations in general health, organ function, pharmacokinetic and pharmacodynamic properties, biological age and physical performance. The intervention group receive a medication review. It is hypothesized that the intervention is feasible and more patients in the intervention group will complete ≥1 deprescribing and/or ≥1 medication optimization 30 days after the beginning of the intervention than the patients in the control group. Secondary it is hypothesized the patients in the intervention group: A. Complete more deprescribing compared to the control group (30 days after intervention) B. Complete more medication optimization compared to the control group (30 days after intervention) C. Have a higher knowledge about own medication (14 days after intervention) D. Have a higher level of satisfaction with medication information (14 days after intervention) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03912103
Study type	Interventional
Source	Region Hovedstadens Apotek
Contact
Status	Completed
Phase	N/A
Start date	March 19, 2019
Completion date	March 5, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02122198` - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women	N/A
Recruiting	`NCT04356924` - Psychological Treatment to Support the Consequences of Cognitive Impairment	N/A
Suspended	`NCT05542238` - The Effect of Acute Exercise on Cardiac Autonomic, Cerebrovascular, and Cognitive Function in Spinal Cord Injury	N/A
Terminated	`NCT04493957` - Evaluation of an Educational Program in the Prevention of the Driving Risks in Patients With Neurocognitive Disorders : ACCOMPAGNE	N/A
Recruiting	`NCT04792983` - Cognition and the Immunology of Postoperative Outcomes
Completed	`NCT06029920` - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment	N/A
Not yet recruiting	`NCT05068323` - Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients	N/A
Completed	`NCT04426838` - Cognitive Behavioral Therapy for Insomnia for the Dementia Caregiving Dyad	N/A
Completed	`NCT04713384` - Remote Bimanual Virtual Rehabilitation Post CVD	N/A
Recruiting	`NCT06284213` - Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
Recruiting	`NCT06053775` - Non-Invasive Brain Stimulation and Cognitive Training for Depressive Symptomatology Related to Breast Cancer (ONCODEP)	N/A
Completed	`NCT03698695` - A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers	Phase 1
Not yet recruiting	`NCT05552729` - Effects of Different Doses of Vitamin D on Cancer-related Cognitive Impairment in Patients With Gastrointestinal Tumors	Phase 1/Phase 2
Recruiting	`NCT03268109` - COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
Completed	`NCT03187353` - IMProving Executive Function Study	Phase 4
Completed	`NCT03301402` - Air Purifier to Improve Endothelial Function and Carotid Intima Thickness	N/A
Completed	`NCT05395559` - Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
Recruiting	`NCT04897334` - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke	N/A
Recruiting	`NCT05030285` - Telehealth Psychotherapy for Anxiety in Persons With Cognitive Impairment	N/A
Recruiting	`NCT04907565` - Impact of Obesity on Post-operative Cognitive Dysfunction: Role of Adipose Tissue

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Interdisciplinary Medication Review Interventions in an Integrated Outpatient Department. — FMA-CPH

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms